Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this registry is to evaluate the semibranch in branched endovascular arotic repair, which is a new tool in endovascular branched aortic repair.
The main question it aims to answer are:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Semibranch CMD branched aortic stentgraft | Device | bEVAR with a custom made abdominal aortic multibranch, which incorporates the semibranch design |
| Measure | Description | Time Frame |
|---|---|---|
| Freedom from target vessel instability | Primary patency and freedom from stenosis of the semibranch | 30 days after intervention |
| Mortality | Overall mortality rate during 30 days after intervention | 30 days after intervention |
| Technical success | cannulation and stentgrafting ot the semibranches | 12 hours after intervention |
| Measure | Description | Time Frame |
|---|---|---|
| Morbidity | Access site, bowel ischemia, kidney failure, paraplegia | During follow up period (up to 3 years) |
| Freedom of Endoleak type I and III | Abscence of endoleaks arising from the semibranch |
Not provided
Not provided
Not provided
Not provided
Patients with pararenal or thoracoabdominal aortic pathology, who are treated with a endovascular semibranch stentgraft
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Muenster University Hospital | Recruiting | Münster | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001014 | Aortic Aneurysm |
| ID | Term |
|---|---|
| D000783 | Aneurysm |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D001018 | Aortic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| During follow up period (up to 3 years) |
| Long term mortality | Overall mortality up to 3 years | During follow up period (up to 3 years) |
| Branch patency | Primary patency of all branches | During follow up period (up to 3 years) |